Compare BridgeBio Pharma Inc (BBIO) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Cytokinetics Inc — how do they compare? BridgeBio Pharma Inc trades at $83.41 (market cap $16.36B), while Cytokinetics Inc trades at $76.67 (market cap $10.63B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| BBIO | CYTK | |
|---|---|---|
Market Cap | $16.36B | $10.63B |
Sector | Health | Technology |
52-Week High | $90.17 | $87.26 |
52-Week Low | $47.29 | $34.31 |
Enterprise Value | $18.14B | $10.74B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
